Education
About Us
Working with TipRanks
Follow Us
Hologic (HOLX)
NASDAQ:HOLX
HOLX Analyst Ratings
Moderate Buy
4 Buy
9 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HOLX Stock 12 Month Forecast
Average Price Target
$77.70
▲(5.03% Upside)
| Highest Price Target$94.00 | Average Price Target$77.70 | Lowest Price Target$69.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Raymond James
$79
Hold
6.79%
Upside
Downgraded
10/22/25
Stephens
$78→$76
Hold
2.73%
Upside
Downgraded
10/22/25
William Blair
―
Hold
―
Downgraded
10/21/25
J.P. Morgan
$80→$78
Hold
5.43%
Upside
Downgraded
10/21/25
Needham
―
Hold
―
Reiterated
10/21/25
Hologic's Acquisition by TPG and Blackstone: Hold Rating Amid Lower Valuation and Antitrust ConcernsWe note that there were previous reports that TPG and Blackstone had offered $16B to take HOLX private but that HOLX turned down this offer. The non-tradable deal CVR of up to $3.00 per share is expected in two payments of $1.50 based upon achievement of certain global revenue goals for HOLX’s Breast Health business in FY26 and FY27 (milestone terms not disclosed). Assuming the CVR is awarded, TPG and Blackstone are paying 17.6x our CY26E EPS estimate (or 16.9x our CY26E EPS if the CVR is not awarded), which is below our large-cap med tech peers, which trades at a median 2026E P/E multiple of 21.7x. However, we believe the discount is warranted since HOLX is growing more slowly than its peers. The transaction is expected to close in F1H26 and includes a 45-day "go-shop" period where HOLX can solicit competing bids.
Leerink Partners
$70→$78
Hold
5.43%
Upside
Reiterated
10/21/25
Hold Rating on Hologic Amid Acquisition by Blackstone and TPG: Limited Impact on Diagnostics SectorWe see limited readthrough to the rest of our Dx coverage, due to the uniqueness of Panther and cytology compared to more CLIA-oriented testing at other labs. The traction is expected to close in calendar 1H26. The deal has been speculated on for a long time and unlikely to be viewed as a surprise by investors. Though this deal is relatively unique and was speculated upon for a while, we do believe M&A sentiment could lift slightly as portfolios are trimmed (WAT-BDX deal [WAT rated OP, BDX not rated]) and as assets are acquired by private equity (HOLX deal).
TR | OpenAI - 4o
$70→$73
Hold
-1.32%
Downside
Reiterated
10/16/25
AI Generated ArticleAI Generated Article
Evercore ISI
$69→$78
Buy
5.43%
Upside
Upgraded
10/07/25
BTIG
―
Hold
―
Reiterated
09/25/25
RBC Capital
$87→$94
Buy
27.06%
Upside
Reiterated
09/02/25
Argus Research
$80
Buy
8.14%
Upside
Upgraded
08/18/25
Mizuho Securities
$70→$75
Buy
1.38%
Upside
Reiterated
07/31/25
Morgan Stanley
$65→$69
Hold
-6.73%
Downside
Reiterated
07/31/25
UBS
$65→$70
Hold
-5.38%
Downside
Reiterated
07/31/25
Bank of America Securities
$64→$70
Hold
-5.38%
Downside
Reiterated
07/18/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Raymond James
$79
Hold
6.79%
Upside
Downgraded
10/22/25
Stephens
$78→$76
Hold
2.73%
Upside
Downgraded
10/22/25
William Blair
―
Hold
―
Downgraded
10/21/25
J.P. Morgan
$80→$78
Hold
5.43%
Upside
Downgraded
10/21/25
Needham
―
Hold
―
Reiterated
10/21/25
Hologic's Acquisition by TPG and Blackstone: Hold Rating Amid Lower Valuation and Antitrust ConcernsWe note that there were previous reports that TPG and Blackstone had offered $16B to take HOLX private but that HOLX turned down this offer. The non-tradable deal CVR of up to $3.00 per share is expected in two payments of $1.50 based upon achievement of certain global revenue goals for HOLX’s Breast Health business in FY26 and FY27 (milestone terms not disclosed). Assuming the CVR is awarded, TPG and Blackstone are paying 17.6x our CY26E EPS estimate (or 16.9x our CY26E EPS if the CVR is not awarded), which is below our large-cap med tech peers, which trades at a median 2026E P/E multiple of 21.7x. However, we believe the discount is warranted since HOLX is growing more slowly than its peers. The transaction is expected to close in F1H26 and includes a 45-day "go-shop" period where HOLX can solicit competing bids.
Leerink Partners
$70→$78
Hold
5.43%
Upside
Reiterated
10/21/25
Hold Rating on Hologic Amid Acquisition by Blackstone and TPG: Limited Impact on Diagnostics SectorWe see limited readthrough to the rest of our Dx coverage, due to the uniqueness of Panther and cytology compared to more CLIA-oriented testing at other labs. The traction is expected to close in calendar 1H26. The deal has been speculated on for a long time and unlikely to be viewed as a surprise by investors. Though this deal is relatively unique and was speculated upon for a while, we do believe M&A sentiment could lift slightly as portfolios are trimmed (WAT-BDX deal [WAT rated OP, BDX not rated]) and as assets are acquired by private equity (HOLX deal).
TR | OpenAI - 4o
$70→$73
Hold
-1.32%
Downside
Reiterated
10/16/25
AI Generated ArticleAI Generated Article
Evercore ISI
$69→$78
Buy
5.43%
Upside
Upgraded
10/07/25
BTIG
―
Hold
―
Reiterated
09/25/25
RBC Capital
$87→$94
Buy
27.06%
Upside
Reiterated
09/02/25
Argus Research
$80
Buy
8.14%
Upside
Upgraded
08/18/25
Mizuho Securities
$70→$75
Buy
1.38%
Upside
Reiterated
07/31/25
Morgan Stanley
$65→$69
Hold
-6.73%
Downside
Reiterated
07/31/25
UBS
$65→$70
Hold
-5.38%
Downside
Reiterated
07/31/25
Bank of America Securities
$64→$70
Hold
-5.38%
Downside
Reiterated
07/18/25
Best Analysts Covering Hologic
1 Month
xxx
Success Rate
7/9 ratings generated profit
Average Return
+3.11%
upgraded a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 77.78% of your transactions generating a profit, with an average return of +3.11% per trade.
3 Months
xxx
Success Rate
6/9 ratings generated profit
Average Return
+1.83%
upgraded a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +1.83% per trade.
1 Year
Success Rate
7/9 ratings generated profit
Average Return
+18.54%
upgraded a buy rating 16 days ago
Copying Vijay Kumar's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +18.54% per trade.
2 Years
xxx
Success Rate
9/9 ratings generated profit
Average Return
+24.52%
upgraded a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +24.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HOLX Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
0
0
0
0
Buy
7
12
11
12
7
Hold
15
22
14
16
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
34
25
28
15
Each month's total comprises the sum of three months' worth of ratings.
HOLX Financial Forecast
HOLX Stock Forecast FAQ
What is HOLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Hologic’s 12-month average price target is 77.70.
What is HOLX’s upside potential, based on the analysts’ average price target?
Hologic has 5.03% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HOLX a Buy, Sell or Hold?
Hologic has a consensus rating of Moderate Buy which is based on 4 buy ratings, 9 hold ratings and 0 sell ratings.
What is Hologic’s price target?
The average price target for Hologic is 77.70. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $94.00 ,the lowest forecast is $69.00. The average price target represents 5.03% Increase from the current price of $73.98.
The highest analyst price target is $94.00 ,the lowest forecast is $69.00. The average price target represents 5.03% Increase from the current price of $73.98.
What do analysts say about Hologic?
Hologic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of HOLX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.